Fidaxomicin Advisory Committee: FDA Wants Advice On The Meaningfulness Of Infection Recurrence
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of Optimer's antibiotic for C. difficile seems assured, but strength of label remains a question.
You may also be interested in...
Communication Of Fidaxomicin's 30-Day Effect Is Question For Labeling Discussions
Anti-Infective Drugs Advisory Committee votes 13-0 to approve the antibiotic for treating Clostridium difficile, but rejects a claim for lowering the risk of recurrence, preferring focus on effect at 30 days.
Communication Of Fidaxomicin's 30-Day Effect Is Question For Labeling Discussions
Anti-Infective Drugs Advisory Committee votes 13-0 to approve the antibiotic for treating Clostridium difficile, but rejects a claim for lowering the risk of recurrence, preferring focus on effect at 30 days.
Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.